# US 2025/0375532 A1 · Dual affinity nanoparticles for the treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375532 A1
- Document ID: US20250375532A1
- Status: Published application
- Kind: A1
- Application number: 19/224,781
- Filed: 2025-05-31
- Published: 2025-12-11
- Earliest claimed: 2024-06-05
- Assignees: Vanderbilt University
- Applicants: Vanderbilt University
- Inventors: Michael R. KING; Maria LOPEZ CAVESTANY; Zhenjiang ZHANG
- Web page: https://patentgrep.com/patent/US20250375532A1

## CPC

- A61K 47/6913: {the liposome being modified on its surface by an antibody}
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 47/6415: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
- A61K 47/6425: {the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell}
- A61K 47/6843: {the antibody targeting a material from animals or humans}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61P 35/00: Antineoplastic agents
- C07K 16/18: against material from animals or humans
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure described bi-functional delivery particles with the ability to bind to two different cell types in a distinct fashion. Employing a first ligand with differential binding capabilities, the delivery particles may bind to a first target, such as cell, in a reversible fashion such that when they encounter a second target (e.g., cell) a second ligand that bind irreversibly to the second target will disrupt the binding to the first target. As such, the first target acts as a carrier to delivery the particle to a diagnostic or therapeutic second target. In particular aspects, the first and second cells are circulating cells.

## Claims

### Claim 1

A delivery particle comprising:
(a) an anti-cancer agent;
(b) a first targeting agent that binds to a non-cancer cell surface moiety; and
(c) a second targeting agent that binds to a cancer cell surface moiety,
wherein the relative affinity of said first targeting agent to said second targeting agent is such that the second targeting agent binding with the cancer cell surface moiety will outcompete the first agent binding with the non-cancer cell surface moiety.

### Claim 2 (depends on 1)

The delivery particle of claim 1, wherein the relative affinities for said first targeting agent and said second targeting agent are less than 100 pN in strength and at least 1000 pN in strength, respectively, such as about 30 pN and about 1000-2000 pN, respectively.

### Claim 3 (depends on 1)

The delivery particle of claim 1, wherein said delivery particle is a bead, a gold particle, a polymeric particle, a vesicle (e.g., nanovesicle), a liposome, a nanoparticle (e.g., lipid nanoparticle), a nanotube, a nanorod, a micelle, or a dendritic macromolecule, such as a lipid nanoparticle comprising phosphatidyl choline, sphingomyelin and cholesterol.

### Claim 4 (depends on 1)

The delivery particle of claim 1, wherein the second targeting agent is an antibody to said cancer cell surface moiety.

### Claim 5 (depends on 1)

The delivery particle of claim 1, wherein the cancer cell surface moiety is vimentin or PSMA.

### Claim 6 (depends on 1)

The delivery particle of claim 1, wherein the first targeting agent is an antibody or receptor for said non-cancer cell surface moiety, such as a receptor for a moiety found on a white blood cell, e.g., wherein the receptor for said non-cancer cell surface moiety is E-selectin, P-selectin, L-selectin or vWF-A1.

### Claim 7 (depends on 1)

The delivery particle of claim 1, wherein the anti-cancer agent is located in an internal phase of said delivery particle, such as a chemotherapeutic agent, a radiotherapeutic agent or a toxin.

### Claim 8 (depends on 1)

The delivery particle of claim 1, wherein the anti-cancer agent is located on the surface of said delivery particle.

### Claim 9 (depends on 1)

The delivery particle of claim 1, wherein the anti-cancer agent is TRAIL or Fas ligand.

### Claim 10 (depends on 1)

The delivery particle of claim 1, wherein the first targeting agent is E-selectin, the second targeting agent is an antibody that binds to vimentin and the anti-cancer agent is TRAIL.

### Claim 11 (depends on 1)

The delivery particle of claim 1, wherein one or more of said anti-cancer agent, said first targeting agent and said second targeting agent are conjugated to the surface of said delivery particle using click chemistry.

### Claim 12 (depends on 1)

The delivery particle of claim 1, wherein the delivery particle is a phase separated liposome comprising at least three lipid types.

### Claim 13 (depends on 12)

The delivery particle of claim 12, wherein the anti-cancer agent is linked to one of said at least three lipid types, and/or said first and/or second targeting agent is linked to one of said at least three lipid types.

### Claim 14 (depends on 1)

The delivery particle of claim 1, wherein the cancer cell is a circulating cancer cell.

### Claim 15 (depends on 1)

The delivery particle of claim 1, wherein the non-cancer cell is a circulating non-cancer cell.

### Claim 16 (depends on 1)

The delivery particle according to claim 1, disposed in a pharmaceutically acceptable carrier or diluent.

### Claim 17

A delivery particle comprising:
(a) a detectable label;
(b) a first targeting agent that binds to a non-cancer cell surface moiety in a reversible fashion; and
(c) a second targeting agent that irreversibly binds to a cancer cell surface moiety.

### Claim at position 18

18-19. (canceled)

### Claim 20 (depends on 1)

A method of targeting a circulating cancer cell in a subject comprising administering to said subject a delivery particle according to claim 1.

### Claim 21 (depends on 20)

The method of claim 20, wherein the subject has cancer, wherein said delivery particle comprises an anti-cancer agent.

### Claim at position 21

22-29. (canceled)

### Claim 30

A delivery particle comprising:
(a) a first targeting agent that binds to a first cell; and
(b) a second targeting agent that binds to a second cell,
wherein the relative affinity of said first targeting agent to said second targeting agent is such that the second targeting agent binding to the second cell surface moiety will outcompete the first agent binding to the first cell surface moiety, resulting in transfer of the delivery particle from the first cell to the second cell, within the dynamic environment of blood flow.
